P
Piotr Czauderna
Researcher at Gdańsk Medical University
Publications - 127
Citations - 5053
Piotr Czauderna is an academic researcher from Gdańsk Medical University. The author has contributed to research in topics: Hepatoblastoma & Medicine. The author has an hindex of 31, co-authored 116 publications receiving 4194 citations. Previous affiliations of Piotr Czauderna include Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group
Derek J. Roebuck,Daniel C. Aronson,Philippe Clapuyt,Piotr Czauderna,Jean de Ville de Goyet,Frédéric Gauthier,Gordon A. MacKinlay,Rudolf Maibach,Kieran McHugh,Øystein E. Olsen,Jean-Bernard Otte,Danièle Pariente,Jack Plaschkes,Margaret Childs,Giorgio Perilongo +14 more
TL;DR: This paper, written by members of the radiology and surgery committees of the International Childhood Liver Tumor Strategy Group (SIOPEL), presents various clarifications and revisions to the original PRETEXT system.
Journal ArticleDOI
Successful Treatment of Childhood High-Risk Hepatoblastoma With Dose-Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR Study
Jozsef Zsiros,Rudolf Maibach,E. Shafford,Laurence Brugières,Penelope Brock,Piotr Czauderna,Derek J. Roebuck,Margaret Childs,Arthur Zimmermann,Véronique Laithier,Jean-Bernard Otte,Beatriz de Camargo,Gordon A. MacKinlay,Marcelo Scopinaro,Daniel C. Aronson,Jack Plaschkes,Giorgio Perilongo +16 more
TL;DR: The applied treatment rendered a great proportion of tumors resectable, and, in comparison with previously published results, led to an improved survival in patients with high-risk hepatoblastoma.
Journal ArticleDOI
Liver transplantation for hepatoblastoma: Results from the International Society of Pediatric Oncology (SIOP) study SIOPEL‐1 and review of the world experience
Jean-Bernard Otte,Jon Pritchard,Doron Aronson,Julia Brown,Piotr Czauderna,Rudolf Maibach,Giorgio Perilongo,E. Shafford,J. Plaschkes +8 more
TL;DR: For hepatoblastoma, total hepatectomy with orthotopic liver transplantation (LTX) has been advocated as the best treatment option and the role of LTX in the overall management of HB is still, however, unclear.
Journal ArticleDOI
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
Giorgio Perilongo,Rudolf Maibach,Elisabeth Shafford,Laurence Brugières,Penelope Brock,Bruce Morland,Beatriz de Camargo,Jozsef Zsiros,Derek J. Roebuck,Arthur Zimmermann,Daniel C. Aronson,Margaret Childs,Eva Widing,Véronique Laithier,Jack Plaschkes,Jon Pritchard,Marcello Scopinaro,Gordon A. MacKinlay,Piotr Czauderna +18 more
TL;DR: Cisplatin monotherapy achieved similar rates of complete resection and survival among children with standard-risk hepatoblastoma and doxorubicin can be safely omitted from the treatment of standard- risk hepatoblowlastoma.
Journal ArticleDOI
Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
Giorgio Perilongo,E. Shafford,Rudolf Maibach,Doron Aronson,Laurence Brugières,Penelope Brock,Margaret Childs,Piotr Czauderna,G. MacKinlay,J.B. Otte,Jon Pritchard,R. Rondelli,Marcelo Scopinaro,C.R. Staalman,Jack Plaschkes +14 more
TL;DR: A treatment strategy based on CDDP monotherapy and surgery thus appears effective in SR-HB but, despite CT intensification, only half of the HR-HB patients are long-term survivors.